Trial · NCT07119372
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 23 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Other | Proportion of subjects (%) who required blood transfusion after switching from Mircera to BCD-131 | Weeks 52-84 | |
| Other | Mean hemoglobin level | Weeks 52-84, Weeks 0-84 | |
| Other | Proportion of subjects (%) with hemoglobin levels of >130 g/L and >140 g/L | Weeks 52-84, Weeks 0-84 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07119372/registered?page=2